BACKGROUND: We performed a prospective randomized trial comparing 5 contrast-enhanced color Doppler (CECD) ultrasound (US) targeted biopsy cores to 10 gray-scale US guided systematic biopsy (SB) cores to determine the impact on the cancer detection rate. METHODS: We prospectively randomized 100 prostate specific antigen (PSA) screening volunteers with an elevated PSA (> or =1.25 ng/ml and free-to-total PSA < 18%) to undergo contrast-enhanced targeted or SB. Contrast-enhanced targeted biopsies with a limited number of five cores were performed into hypervascular areas of the peripheral zone (PZ) during administration of the US contrast agent SonoVue (Bracco, Italy). A subjective grading of the vascularity from 0 to 3 was used: grade 0, no color signal; 1, low density; 2, medium density; and 3, high density of color signals. Ten SBs were obtained in a standard spatial distribution. Cancer detection rates were compared in the groups. RESULTS:Cancer was detected in 16/50 subjects (32%) by targeted biopsy, and in 13/50 patients (26%) with SB. The cancer detection rate was significantly better for the targeted approach (P < 0.04, McNemar). The detection rate for targeted biopsy cores (15.6% or 39/250 cores) was significantly better than for SB cores (6.8% or 34/500 cores, P < 0.001, McNemar). CONCLUSIONS: CECD targeted biopsy detected more cancers than SB with a reduced number of biopsy cores.
RCT Entities:
BACKGROUND: We performed a prospective randomized trial comparing 5 contrast-enhanced color Doppler (CECD) ultrasound (US) targeted biopsy cores to 10 gray-scale US guided systematic biopsy (SB) cores to determine the impact on the cancer detection rate. METHODS: We prospectively randomized 100 prostate specific antigen (PSA) screening volunteers with an elevated PSA (> or =1.25 ng/ml and free-to-total PSA < 18%) to undergo contrast-enhanced targeted or SB. Contrast-enhanced targeted biopsies with a limited number of five cores were performed into hypervascular areas of the peripheral zone (PZ) during administration of the US contrast agent SonoVue (Bracco, Italy). A subjective grading of the vascularity from 0 to 3 was used: grade 0, no color signal; 1, low density; 2, medium density; and 3, high density of color signals. Ten SBs were obtained in a standard spatial distribution. Cancer detection rates were compared in the groups. RESULTS:Cancer was detected in 16/50 subjects (32%) by targeted biopsy, and in 13/50 patients (26%) with SB. The cancer detection rate was significantly better for the targeted approach (P < 0.04, McNemar). The detection rate for targeted biopsy cores (15.6% or 39/250 cores) was significantly better than for SB cores (6.8% or 34/500 cores, P < 0.001, McNemar). CONCLUSIONS:CECD targeted biopsy detected more cancers than SB with a reduced number of biopsy cores.
Authors: Gianluigi Taverna; Giorgio Bozzini; Fabio Grizzi; Mauro Seveso; Alberto Mandressi; Luca Balzarini; Federica Mrakic; Pietro Bono; Oliviero De Franceco; NicolòMaria Buffi; Giovanni Lughezzani; Massimo Lazzeri; Paolo Casale; Giorgio Ferruccio Guazzoni Journal: World J Urol Date: 2015-10-19 Impact factor: 4.226
Authors: Michael Josef Mitterberger; Friedrich Aigner; Wolfgang Horninger; Hanno Ulmer; Silvio Cavuto; Ethan J Halpern; Ferdinand Frauscher Journal: Eur Radiol Date: 2010-06-23 Impact factor: 5.315
Authors: Michael Mitterberger; Wolfgang Horninger; Friedrich Aigner; Germar M Pinggera; Ilona Steppan; Peter Rehder; Ferdinand Frauscher Journal: Cancer Imaging Date: 2010-03-03 Impact factor: 3.909